In this session, speakers will give a brief overview on the most important considerations for the production of radiopharmaceuticals for therapy under GMP, including regulations, situation and use of synthesis modules, shielding, and how the preparation of MRT agents might be incorporated into the clinical routine. A practical example of GMP manufacture of an alpha particle emitting antibody will also be covered.
- Pei San Chan – Royal Free London NHS Foundation Trust, UK
- Professor Jon Wadsley – Weston Park Hospital (Introduction)
- Dr Maggie Cooper – King’s College London (Good manufacturing practice for molecular radiotherapy)
- Mr Clint Zvavamwe – University Hospital Southampton NHS Foundation Trust (Manufacturing of Thorium Targeted Conjugates PSMA & MSLN)
Sessions in the series:
- 3 June 2021 – Access to novel radiopharmaceuticals in the UK (recording available)
- 8 July 2021 – What is possible with dosimetry and why is it necessary? (recording available)
- 16 September 2021 – Radiobiology of molecular radiotherapy (available to book)
- 7 October 2021 – Radiochemistry/radiopharmacy for clinical trials of molecular radiotherapies (available to book)
- 4 November 2021 – Trial methodology and health economic considerations
- Date TBC – Routes to funding MRT research
- Date TBC – MRT trial proposals guidance workshop
Who should attend?
Clinicians, physicists, radiopharmacists, radiochemists, radiobiologists, technologists and researchers with an interest in molecular radiotherapy.